A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Biomaterials are materials designed to interface with biological systems for therapeutic or diagnostic purposes. Tissue engineering combines scaffolds (3D porous structures), cells, and biochemical signals to regenerate damaged tissues. Key properties: (1) Biocompatibility — minimizing immune response, promoting cell attachment and proliferation; (2) Mechanical Match — scaffold stiffness should match native tissue to guide mechanical cues (e.g., soft scaffolds for cartilage, stiff for bone); (3) Biodegradation — controlled resorption as new tissue forms, with degradation products non-toxic; (4) Porosity and Architecture — pore size 10–300 μm for cell infiltration, interconnected for nutrient diffusion. Materials span natural (collagen, hyaluronic acid, chitosan), synthetic (poly(lactic-co-glycolic) acid, polyurethane), and hybrid. Scaffold fabrication uses electrospinning (nanofibers), 3D printing (precise geometry), salt leaching, freeze-drying, and microfluidics.
Characterize a commercial scaffold (e.g., collagen sponge, electrospun PLGA nanofiber mat): measure porosity via mercury porosimetry or SEM image analysis, determine pore size distribution, measure mechanical properties (compression, tension). Culture mammalian cells (fibroblasts, osteoblasts) on the scaffold, observing attachment (SEM, fluorescent microscopy), proliferation (cell counting, metabolic assays), and gene expression (qPCR for markers of differentiation). Design a scaffold experiment: alter fiber diameter, pore size, or stiffness and measure impact on cell behavior. Compare to native tissue properties (mechanical, structural, biochemical).
Biomaterials are materials designed to coexist with living tissue, either temporarily (a biodegradable scaffold) or permanently (a joint replacement, dental implant). They bridge materials science, biology, and medicine. The challenge is not just to be "non-toxic" (many materials achieve that) but to actively guide tissue repair, regeneration, and integration.
Tissue Engineering combines three elements: (1) Scaffold — a 3D porous structure that provides mechanical support and a platform for cells to attach and organize; (2) Cells — patient-derived or allogeneic cells (fibroblasts, osteoblasts, chondrocytes, stem cells) that synthesize the extracellular matrix (ECM) and form functional tissue; (3) Biochemical/mechanical signals — factors (growth factors, peptides) and mechanical cues (stiffness, stretch) that guide cell behavior toward desired differentiation and ECM composition.
Scaffold materials span a spectrum:
Key design considerations:
1. Biocompatibility: The scaffold must not trigger strong immune response. This requires controlling protein adsorption (which can modify surface properties), cell adhesion (should be cell-type-specific), and degradation products (must be non-toxic, removable from the implant site). Surface modification (PEGylation, peptide coating) often improves compatibility.
2. Mechanical Properties: A bone scaffold needs high stiffness (E ~1–10 GPa) to bear load and provide osteogenic signals. Cartilage is softer (E ~0.1–1 MPa) and requires different mechanical cues. Mechanotransduction — the cell's ability to sense and respond to mechanical forces — means stiffness alone guides differentiation: mesenchymal stem cells on soft substrates (E ~1 kPa, like brain tissue) differentiate into neurons; on medium stiffness (E ~10 kPa, like muscle), into muscle cells; on stiff substrates (E ~100+ kPa, like bone), into osteoblasts. This is a powerful design tool: choose the scaffold stiffness to match the target tissue and naturally guide cells toward appropriate differentiation.
3. Degradation Kinetics: The scaffold should gradually resorb as new tissue forms, eventually being completely replaced. Too-fast degradation leaves gaps before new tissue fills them (mechanical failure); too-slow degradation persists and can inhibit new ECM deposition. The kinetics depend on polymer hydrophilicity, cross-linking density, and enzymatic accessibility. PLGA degrades over weeks to months; collagen can be tuned from days to years via cross-linking. Ideally, degradation rate matches tissue formation rate, a design target that is application-specific.
4. Porosity and Pore Architecture: Pore size controls cell infiltration (cells are ~10–20 μm; pores should be 10–300 μm to allow cell migration while providing adequate surface area). Interconnected pores enable nutrient diffusion (cells beyond ~200 μm from blood supply need oxygen and nutrient diffusion; interconnected pores increase effective diffusion distance). Pore size can be tuned via processing: electrospinning yields nanofiber mats (fiber diameter 50–1000 nm); salt leaching creates micron-scale pores; freeze-drying creates larger pores; 3D printing offers precise geometric control.
5. Biochemical Signals: Growth factors (VEGF, BMP, FGF) incorporated in the scaffold guide cell behavior. Delivery can be bolus (quick release, short-lived signal) or sustained (encapsulation in microspheres, release over weeks). Peptide signals (RGD for cell adhesion, cryptic epitopes exposed upon proteolysis) can be covalently tethered to the scaffold. This allows spatiotemporal control: release growth factors at the right time and place to guide tissue formation.
Vascularization is a grand challenge. Tissues thicker than ~200 μm (the diffusion limit for oxygen) require blood vessels. Strategies include: promoting endothelial cell infiltration (via pore size, angiogenic factors), pre-vascularization (culturing endothelial cells in the scaffold in vitro to form capillary networks), microfluidic design (engineering miniature blood vessels), and angiogenic factor delivery (VEGF, FGF). Complete solution remains elusive; this is an active research frontier.
Clinical Applications:
Regulatory and economic challenges: Tissue-engineered products must be proven safe and effective via clinical trials, a lengthy and expensive process. Manufacturing scale-up requires Good Manufacturing Practice (GMP), adding cost. Current products are expensive (~$1000–10,000 per graft), limiting accessibility. Research is accelerating toward simpler, more robust constructs and biofabrication methods (3D printing, microfluidics) that reduce cost and improve reproducibility. The ultimate goal: "off-the-shelf" tissue constructs that require minimal customization, reducing cost and enabling wider clinical adoption.
No topics depend on this one yet.